



Release of De-Identified INSPECT Data

Policy

The Indiana Board of Pharmacy (Board) may release de-identified data¹ for research or educational purposes in accordance with the requirements set forth herein.

Applicable Laws

IC 35-48-7-11.1 Confidentiality

...

(j) The board may compile statistical reports from the information described in subsection (a). The reports must not include information that identifies any practitioner, ultimate user, or other person administering a controlled substance. Statistical reports compiled public records.

Protocol for Release of De-Identified Data

Researcher must apply for the release of the de-identified data by (a) submitting a protocol and institutional review board (IRB) application and approval for Board review and, if deemed necessary by the Board, (b) making a personal appearance in front of the INSPECT Subcommittee.² The Board will place the application on its meeting agenda.

Board will review protocol and grant or deny the application to release the de-identified data based on the following factors:

1. The reason for the study and anticipated outcome (e.g. publication, presentation at scientific meeting, etc.);
2. Data fields and time frame requested;
3. Agreement that use of the data is limited to the protocol terms;
4. Agreement that the data cannot be transferred/shared with anyone outside the specific research project for which it is approved;
5. Agreement that research results will be reported to the INSPECT Subcommittee and approved by the Subcommittee prior to publication;
6. Agreement that the Indiana Board of Pharmacy and INSPECT may use the results for Board related purposes (e.g. reports to legislature); and
7. Any other information the Board deems necessary to render a decision on the application.

¹ De-identified data is defined below under the heading "INSPECT De-identified Data Defined".

² The institutional review board (IRB) must be registered with the Office for Human Research Protections (OHRP).



If data is to be re-used, another protocol and IRB approval is required. INSPECT staff will track all approved protocols and retain a copy of all data released pursuant to protocol. For good cause shown, the Board reserves the right to waive these policy requirements.

INSPECT De-identified Data Defined

Specific fields a de-identified data file will contain: (Based off SHOPPER.rpt)

**INSPECT will not perform any type of sorting or analysis, only the data dump.*

1. Zip Code
2. Date Rx Written
3. Date Filled
4. Quantity
5. Days Supply
6. Drug Information
7. Dispensing Pharmacy
8. Payment Type

INSPECT will NOT provide:

- DEA Numbers
- Patient address
- Patient names
- Customer ID Numbers
- A report on a "specific" product or single drugs, e.g. Oxycontin, Hydrocodone.

INSPECT may provide customized data:

- By Schedule – All schedule IIs, schedule II & III together, etc.
- By Drug Type – Pain Reliever, Sedative, Stimulant or Tranquilizer families
- ANY BJA/Governor Metric